Target intelligence / Profile preview

Cytoplasmic polyadenylation element binding protein 3 (CPEB3)

Target
CPEB3
Molecular classification
RNA-binding protein, Translational regulator, Prion-like protein, CPEB protein family
01

Overview

Cytoplasmic polyadenylation element binding protein 3 (CPEB3) is a **sequence-specific RNA-binding protein** that acts as a translational repressor in the basal state and a translational activator following neuronal stimulation[5]. It does not bind canonical cytoplasmic polyadenylation elements (CPEs), but rather binds to U-rich loop structures in target mRNAs. CPEB3 regulates translation of key synaptic proteins, including glutamate receptor subunits and actin, and is essential for hippocampal-dependent long-term memory[3][5]. It localizes to both the nucleus and cytoplasm, shuttling in a regulated manner, and accumulates in P bodies where it represses translation through mRNA deadenylation and decay[3]. CPEB3 possesses a prion-like domain that may mediate durable changes in protein function, influencing learning and memory. Mutations, dysregulation, or improper function of CPEB3 are implicated in neurodevelopmental and cognitive diseases such as Fragile X syndrome[5][6].

Other names
CPEB3CPEB-3
02

Mechanism of action

No approved drugs; mechanistically, CPEB3 inhibits translation by localizing mRNAs to cytoplasmic P bodies, represses via deadenylation and decay, and can switch to activation in response to synaptic stimuli

03

Biological functions

Translational repression and activation (context-dependent; repression in basal state, activation after neuronal stimulation)mRNA deadenylation and decayRegulation of synaptic plasticity, learning, and memoryRegulation of actin translation, glutamate receptor subunits (GRIA1, GRIA2, GRIN1, GRIN2A, GRIN2B), DLG4, TRPV1, SUMO2Inhibition of STAT5B transcriptional activity
04

Disease associations

Fragile X syndromeImplicated in cognitive disorders (memory consolidation and maintenance)Cancer etiology (emerging data)Neurodevelopmental and neurodegenerative disease (studied in models)
05

Safety considerations

Not established due to absence of direct pharmacological targeting; theoretical challenges would include pleiotropic roles in memory and neuronal function
06

Biomarkers

Expression of CPEB3 may be relevant as a biomarker in studies of Fragile X syndrome, cognitive function/memory disorders, but no validated clinical biomarker use

Beyond the preview

Go deeper on Cytoplasmic polyadenylation element binding protein 3 (CPEB3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytoplasmic polyadenylation element binding protein 3 (CPEB3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call